Value proposition

REINVENTING CARDIAC DRUG DISCOVERY

HeartBeat.bio is building the worldwide first high-throughput human organoid cultivation, screening and AI-supported data analysis solution for developing first-in-class drugs to treat heart failure faster, less expensively and with a higher probability of success in clinical trials. The so-called Cardioid Drug Discovery Platform relies on self-assembling, highly reproducible cardiac organoids which recapitulate the human physiology and enable modeling of heart diseases in a way not achieved with other in-vitro systems. Currently, HeartBeat.bio is focused on drug-induced and different sub-types of genetic cardiomyopathies, followed by programs in diabetic cardiomyopathy, myocardial infarction, and cardiac remodeling. HeartBeat.bio was founded in 2021 based on technology from the Institute of Molecular Biotechnology (IMBA) and is located at the Vienna BioCenter in Austria.

Cardiac Organoids, Human 3D Disease Modelling , High-Throughput Drug Discovery Platform, Cardiac Drug Discovery, Heart Failure, Cardiomyopathy, Heart Regeneration, Myocardial Infarction, Cardiotoxicity, Cardio-Oncology, and iPS Cells